Pipeline

Global

Designated Asian Regions

Mainland China, Hong Kong, Macao and Taiwan

China

Overseas

Product	Rights Authorized Region**	Indication	Clinical Trial Approval	Clinical Trial for Registration	Marketing Application	Marketed	Major Marketed Regions**
							CN	US	EU	JP
Diazepam Nasal Spray		Intermittent, stereotypic episodes of frequent seizure activity (i.e. seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older					√ 2023.6.7	√
Tildrakizumab Solution for Injection (Biological Agent)		Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy					√ 2023.5.26	√	√	√
Methotrexate Injection		Severe recalcitrant disabling psoriasis, which is not adequately responsive to other forms of therapy such as phototherapy, PUVA, and retinoids					√ 2023.3.24		√
		Adult rheumatoid arthritis							√	√
Methylthioninium Chloride Enteric-coated Sustained-release Tablets		An diagnostic agent to enhance visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy							√
Desidustat Tablets		Anemia in patients with chronic kidney disease
Cyclosporine Eye Drops 0.09%		Increasing tear secretion in patients with keratoconjunctivitis sicca (dry eye)						√
PLENITY		An aid for weight management in adults with a BMI of 25-40 kg/m2 when used in conjunction with diet and exercise						√	√
Latanoprost Eye Drops		Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension						√
Ruxolitinib cream		Topical treatment of nonsegmental vitiligo in adults and pediatric patients aged 12 years of age and older						√	√
		Topical short-term and non-continuous chronic treatment of mild to moderate eczema (atopic dermatitis) in non-immunocompromised adult and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable						√
Levetiracetam XR Tablet		Adjunctive therapy for the treatment of partial-onset seizures						√
BCG for Intravesical Instillation (Biological Agent)	*	Non-invasive urothelial bladder carcinoma, including curative treatment of carcinoma in situ and prophylactic treatment of recurrence							√
PoNS		Chronic balance deficit due to mild-to-moderate traumatic brain injury

* Taiwan is not included in the rights authorized region of BCG for Intravesical Instillation
** Major Marketed Regions indicate where products are approved. CMS’s rights are stated by Rights Authorized Region, CMS has NO development, commercialization or other product rights in unauthorized regions. Please refer to local prescribing information for more information, including full safety information, on CMS’s marketed medicines, or on medicines marketed by CMS’s collaboration partners.
Updated as at 31 August 2023